Antiviral Drugs - Southern Europe

Southern Europe

The projected revenue in the Antiviral Drugs market in Southern Europe is expected to reach US$1.59bn in 2024.
Looking ahead, the market is anticipated to exhibit a steady annual growth rate (CAGR 2024-2029) of 1.23%, leading to a market volume of US$1.69bn by 2029.
In comparison to other regions worldwide, United States is forecasted to generate the highest revenue in the market, amounting to US$30,640.00m in 2024.
In Southern Europe, Italy is leading the way in the development and production of antiviral drugs, with a strong focus on research and innovation.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Antiviral Drugs in Southern Europe has been on the rise in recent years.

Customer preferences: Antiviral Drugs have become increasingly popular due to the growing incidence of viral diseases in Southern Europe. Customers are becoming more aware of the benefits of using antiviral drugs to treat viral infections, which has led to an increase in demand for these drugs.

Trends in the market: One of the major trends in the Antiviral Drugs market in Southern Europe is the increasing use of generic drugs. Due to the high cost of branded drugs, customers are opting for cheaper generic drugs, which has led to increased competition among pharmaceutical companies. Another trend is the increasing focus on research and development of new antiviral drugs, which has led to the introduction of new and more effective drugs in the market.

Local special circumstances: Southern Europe has a high incidence of viral diseases, such as influenza, hepatitis, and HIV/AIDS. The region is also home to a large aging population, which is more susceptible to viral infections. These factors have contributed to the high demand for antiviral drugs in the region.

Underlying macroeconomic factors: The Antiviral Drugs market in Southern Europe is influenced by several macroeconomic factors. One of the most important factors is the level of healthcare spending in the region. As healthcare spending increases, the demand for antiviral drugs is likely to increase as well. Another factor is the level of government regulation in the pharmaceutical industry. Stringent regulations can make it difficult for pharmaceutical companies to introduce new drugs in the market, which can limit the growth of the Antiviral Drugs market in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.